Canada
· Delayed Price · Currency is CAD MYND Life Sciences Statistics
Total Valuation
MYND Life Sciences has a market cap or net worth of CAD 1.67 million. The enterprise value is 4.67 million.
| Market Cap | 1.67M |
| Enterprise Value | 4.67M |
Important Dates
The last earnings date was Thursday, August 29, 2024.
| Earnings Date | Aug 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MYND Life Sciences has 47.82 million shares outstanding. The number of shares has increased by 1.27% in one year.
| Shares Outstanding | 47.82M |
| Shares Change (YoY) | +1.27% |
| Shares Change (QoQ) | -1.64% |
| Owned by Insiders (%) | 27.88% |
| Owned by Institutions (%) | n/a |
| Float | 33.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.73 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.89 |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -13.41 |
| Interest Coverage | -3.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -147.79% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.22% in the last 52 weeks. The beta is 0.40, so MYND Life Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -22.22% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 50.89 |
| Average Volume (20 Days) | 1,789 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MYND Life Sciences had revenue of CAD 1 and -694,069 in losses. Loss per share was -0.01.
| Revenue | 1 |
| Gross Profit | -324,337 |
| Operating Income | -1.26M |
| Pretax Income | -694,069 |
| Net Income | -694,069 |
| EBITDA | -1.26M |
| EBIT | -1.26M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 1,807 in cash and 3.00 million in debt, giving a net cash position of -3.00 million or -0.06 per share.
| Cash & Cash Equivalents | 1,807 |
| Total Debt | 3.00M |
| Net Cash | -3.00M |
| Net Cash Per Share | -0.06 |
| Equity (Book Value) | -5.61M |
| Book Value Per Share | -0.12 |
| Working Capital | -5.61M |
Cash Flow
In the last 12 months, operating cash flow was -222,343 and capital expenditures -1,306, giving a free cash flow of -223,649.
| Operating Cash Flow | -222,343 |
| Capital Expenditures | -1,306 |
| Free Cash Flow | -223,649 |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | -125,864,900.00% |
| Pretax Margin | -69,406,900.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -22,364,900.00% |
Dividends & Yields
MYND Life Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.27% |
| Shareholder Yield | -1.27% |
| Earnings Yield | -41.95% |
| FCF Yield | -13.36% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MYND Life Sciences has an Altman Z-Score of -35.29. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -35.29 |
| Piotroski F-Score | n/a |